Figure 4. Monitoring the response to anti-angiogenic drug in GBM bearing mice by [¹⁸F]FET PET imaging. Representative transverse plane of PET image showing bevacizumab response on Days 7 and 12 after initiation of treatment (A). Scale bar represents 0.5–2.0 g/mL of [¹⁸F]FET. Quantitative [¹⁸F]FET uptake in tumor of each group over time is shown (B). Values represent mean±SD of each group. ^*P<0.05 vs. control group determined by the Dunnett's test after ANOVA multiple comparison.